The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Management of ocular events in patients treated with belantamab mafodotin plus PomDex in DREAMM-8
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, The University of Melbourne, Melbourne, Australia, discusses the management of ocular events in patients with multiple myeloma who were treated with belantamab mafodotin plus pomalidomide and dexamethasone (PomDex) in the DREAMM-8 trial (NCT04484623). This was the most common toxicity associated with belantamab mafodotin in this trial, and it was typically managed with dose delays and reductions. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
